Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition

Table 1 Demographic data of the complete study cohort for the main experiments (PiB– vs PiB+)

	Group (total, n = 353)
Basic characteristic	PiB– (n = 253)	PiB+ (n = 100)	P value^a
Global PiB deposition, mean ± SEM	1.11 ± 0.004	1.91 ± 0.038	<0.001
Clinical diagnosis, N/M/D	187/50/16	28/29/43	<0.001^†
Gender, male/female	95/158	38/62	>0.05^†
Age (years), mean ± SEM	69.94 ± 0.5	73.00 ± 0.7	<0.001
CDR, mean ± SEM	0.15 ± 0.02	0.5 ± 0.04	<0.001
MMSE z score,^b mean ± SEM	–0.13 ± 0.07	–1.91 ± 0.20	<0.001
Education, mean ± SEM	10.65 ± 0.3	10.82 ± 0.5	>0.05
ApoE4-positive, n/N (%)	39/253 (15%)	57/100 (57%)	<0.001^†

Details of clinical diagnosis and pathological states (CDR score, MMSE z score, and global PiB deposition (SUVR)) of each subject are shown in Additional file 3
PiB Pittsburgh-compound B, SUVR standardized uptake value ratio, – or + PiB-PET positivity, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating, ApoE apolipoprotein E, SEM standard error of mean, n number of subjects, N/M/D cognitively normal/mild impairment/dementia
^a P value, significance by unpaired t-test except for clinical diagnosis, gender, and ApoE
^bA revised value of the MMSE score with consideration for age, gender, and education level
^†Pearson’s chi-square test

ISSN: 1758-9193